The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 31915452 · doi:10.1155/2019/7918631
What was done
A systematic review and meta-analysis of 12 randomized controlled trials identified from PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases through May 30, 2019. The authors evaluated the efficacy and safety of berberine on reproductive, endocrine, and metabolic parameters compared to placebo, no treatment, metformin, or letrozole in women with polycystic ovary syndrome (PCOS). Data synthesis was performed using RevMan 5.3.
What was found
Berberine showed live birth rates similar to placebo or metformin, but lower than letrozole (RR: 0.61, 95% CI: 0.44 to 0.82). Compared to placebo or no treatment, berberine reduced total testosterone and the LH/FSH ratio (8 RCTs, n = 577, MD: -0.34, 95% CI: -0.47 to -0.20; and 3 RCTs, n = 179, MD: -0.44, 95% CI: -0.68 to -0.21, respectively). Compared to metformin, berberine reduced total cholesterol (3 RCTs, n = 201, MD: -0.44, 95% CI: -0.60 to -0.29), waist circumference (3 RCTs, n = 197, MD: -2.74, 95% CI: -4.55 to -0.93), and waist-to-hip ratio (4 RCTs, n = 258, MD: -0.04, 95% CI: -0.05 to -0.03), with no significant difference in BMI (4 RCTs, n = 262, MD: -0.03, 95% CI: -0.46 to 0.39). Gastrointestinal adverse events (3 RCTs, n = 567, RR: 1.01, 95% CI: 0.76 to 1.35) and serious pregnancy adverse events (RR: 0.98, 95% CI: 0.70 to 1.37) were comparable to placebo.
Why it matters
Berberine does not improve fertility outcomes over standard therapies like letrozole, but it may offer metabolic and endocrine benefits, particularly in lipid and androgen management, without increasing gastrointestinal side effects relative to placebo.
Limits
Individual outcome analyses included small numbers of trials and limited participant counts (several analyses had under 200–300 participants). The abstract does not specify treatment durations, dosages, diagnostic criteria used across trials, or long-term clinical endpoints.
Cited by
- partial Berberine increases insulin sensitivity, functioning similarly to metformin but with fewer side effects.